Dr. Sadelain on CAR T-Cell Therapies
April 10th 2015Michel Sadelain, MD, PhD, Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center (MSK), discusses chimeric antigen receptor (CAR) t-cell therapies.
Dr. Brentjens on CAR T-Cell Therapy Challenges
January 30th 2015Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, talks about the challenges of Chimeric Antigen Receptor (CAR) T-Cell therapies for the treatment of hematologic cancers.
Dr. Park on Using CD19-Targeted CAR T Cells as Treatment for ALL
December 16th 2014Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.